Explore /
Poster
/ Phase I/II study of the PI3Kβ inhibitor GSK2636771 in combination with pembrolizumab (P) in patients (pts) with PD-1 refractory metastatic melanoma (MM) and PTEN loss.

Phase I/II study of the PI3Kβ inhibitor GSK2636771 in combination with pembrolizumab (P) in patients (pts) with PD-1 refractory metastatic melanoma (MM) and PTEN loss.

Authors

Hussein Abdul-Hassan Tawbi

The University of Texas MD Anderson Cancer Center, Houston, TX

Hussein Abdul-Hassan Tawbi , Weiyi Peng , Denai Milton , Rodabe Navroze Amaria , Isabella Claudia Glitza , Wen-Jen Hwu , Sapna Pradyuman Patel , Michael K.K. Wong , Scott Eric Woodman , Cassian Yee , Jennifer Leigh McQuade , Michael T. Tetzlaff , Alexander J. Lazar , Suzanne Cain , Elizabeth M. Burton , Jan Hendrik Beumer , Patrick Hwu , Michael A. Davies

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

Poster Details

Meeting

2018 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Melanoma/Skin Cancers

Track

Melanoma/Skin Cancers

Sub Track

Advanced/Metastatic Disease

Clinical Trial Registration Number

NCT03131908

Citation

J Clin Oncol 36, 2018 (suppl; abstr TPS9596)

DOI

10.1200/JCO.2018.36.15_suppl.TPS9596

Abstract #

TPS9596

Poster Bd #

422b

Abstract Disclosures

Similar Posters

Poster

2022 ASCO Annual Meeting

$ATTAC-MCC: Phase I/II study of autologous CD8+ and CD4+ transgenic T cells expressing a high affinity MCPyV-specific TCR combined with checkpoint inhibitors and class I MHC-upregulation in patients with metastatic MCC refractory to PD-1 axis blockade.$